Penumbra (NYSE:PEN) Cut to Hold at Baird R W

Baird R W downgraded shares of Penumbra (NYSE:PEN) from a strong-buy rating to a hold rating in a research report report published on Friday morning,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Robert W. Baird reiterated a “neutral” rating and set a $374.00 price objective (up previously from $345.00) on shares of Penumbra in a report on Friday. BTIG Research lowered Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 target price for the company. in a research report on Thursday. Leerink Partners lowered Penumbra to a “market perform” rating in a report on Friday. Wells Fargo & Company reissued an “equal weight” rating and issued a $374.00 price objective on shares of Penumbra in a research note on Thursday. Finally, Piper Sandler lowered Penumbra from an “overweight” rating to a “hold” rating and set a $374.00 target price on the stock. in a research report on Thursday. Seven analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $355.88.

Penumbra Price Performance

Penumbra stock opened at $350.93 on Friday. The stock has a 50-day moving average price of $303.54 and a two-hundred day moving average price of $269.79. Penumbra has a 12 month low of $221.26 and a 12 month high of $352.15. The company has a market capitalization of $13.74 billion, a PE ratio of 83.95, a P/E/G ratio of 2.14 and a beta of 0.71. The company has a current ratio of 6.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.07. The firm had revenue of $354.69 million during the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The company’s revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.85 EPS. Analysts expect that Penumbra will post 3.67 EPS for the current year.

Insider Activity

In related news, EVP Johanna Roberts sold 300 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the sale, the executive vice president directly owned 63,836 shares of the company’s stock, valued at approximately $19,159,098.68. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Harpreet Grewal sold 186 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total value of $58,151.04. Following the completion of the transaction, the director owned 8,230 shares of the company’s stock, valued at $2,573,027.20. This trade represents a 2.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 34,144 shares of company stock valued at $10,260,127. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Mather Group LLC. purchased a new stake in shares of Penumbra in the third quarter worth about $25,000. Newbridge Financial Services Group Inc. purchased a new stake in Penumbra in the 2nd quarter worth approximately $30,000. Rothschild Investment LLC purchased a new stake in Penumbra in the 3rd quarter worth approximately $40,000. Parkside Financial Bank & Trust boosted its holdings in Penumbra by 70.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after purchasing an additional 66 shares during the period. Finally, Covestor Ltd grew its position in shares of Penumbra by 53.0% during the 3rd quarter. Covestor Ltd now owns 179 shares of the company’s stock valued at $46,000 after purchasing an additional 62 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

Key Stories Impacting Penumbra

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.